Unavailable
Unavailable
Save time and jump to the most important pieces.
SAN RAFAEL, Calif., Oct. 28, 2024 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (NASDAQ:EKSO) (the "Company"), an industry leader in exoskeleton technology for medical and industrial use, today reported financial results for the three and nine months ended September 30, 2024. Recent Highlights and Accomplishments Reported revenue of $4.1 million in the third quarter of 2024Sold a total of 33 EksoHealth devices in the third quarter of 2024Announced receipt of initial Centers for Medicare & Medicaid Services ("CMS") reimbursement for Ekso Indego PersonalAchieved gross margin of 53.5% in the third quarter of 2024Completed underwritten offering resulting in net proceeds of approximately $5
SAN RAFAEL, Calif., Oct. 21, 2024 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (NASDAQ:EKSO) (the "Company"), an industry leader in exoskeleton technology for medical and industrial use, today announced that it will release financial and business results for the third quarter 2024 after the close of trading on Monday, October 28, 2024. Management will host a conference call beginning at 1:30 p.m. PT / 4:30 p.m. ET to discuss the financial results and recent business developments. A live webcast of the event will be available in the "Investors" section of the Company's website at www.eksobionics.com, or by clicking here. Investors interested in listening to the conference call may do so
SAN RAFAEL, Calif., Aug. 29, 2024 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (NASDAQ:EKSO) (the "Company" or "Ekso Bionics"), an industry leader in exoskeleton technology for medical and industrial use, today announced the pricing of an underwritten public offering of 6,000,000 total units and pre-funded units for gross proceeds of approximately $6.0 million prior to deducting underwriting discounts and commissions and offering expenses. The offering is comprised of 3,100,000 units, priced at a public offering price of $1.00 per unit, with each unit consisting of one share of common stock, one warrant to purchase one share of common stock at an exercise price of $1.00 per share that e
Brings Strategic Healthcare Expertise and Extensive Experience with the U.S. Department of Veterans Affairs (VA) to Ekso's Board Deborah Lafer Scher SAN RAFAEL, Calif., June 17, 2024 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (NASDAQ:EKSO) (the "Company"), an industry leader in exoskeleton technology for medical and industrial use, today announced the appointment of Deborah Lafer Scher to its Board of Directors, effective June 6, 2024. "We are pleased to strengthen our Board with the addition of Deborah Lafer Scher, a distinguished leader who brings a wealth of healthcare experience and a proven track record of business development expertise," said Scott Davis, President and Chie
Broadens Ekso Bionics' product portfolio into home use Adds Vanderbilt University as a key commercial and research partner Acquisition consolidates leading lower extremity robotic companies Ekso President and COO Scott Davis promoted to Chief Executive Officer; Steven Sherman to remain Chairman, appointed Executive Chair SAN RAFAEL, Calif., Dec. 05, 2022 (GLOBE NEWSWIRE) -- Ekso Bionics (NASDAQ:EKSO) (the "Company"), an industry leader in exoskeleton technology for medical and industrial use, today announced the acquisition of the Human Motion and Control ("HMC") Business Unit from Parker Hannifin Corporation ("Parker"), a global leader in motion and control technologies. The acquisiti
RICHMOND, Calif., May 26, 2022 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (NASDAQ:EKSO) (the "Company"), an industry leader in exoskeleton technology for medical and industrial use, today announced the appointment of Jerome Wong as Interim Chief Financial Officer following the departure of current CFO Jack Glenn. Mr. Glenn resigned effective June 17, 2022 to pursue a new position at another public company. Mr. Glenn's resignation is not the result of any dispute or disagreement with the Company including any matters relating to the Company's accounting practices or financial reporting. "I am excited that Jerome has accepted the Interim CFO role after having served as our Controll
4 - EKSO BIONICS HOLDINGS, INC. (0001549084) (Issuer)
SAN RAFAEL, Calif., Oct. 21, 2024 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (NASDAQ:EKSO) (the "Company"), an industry leader in exoskeleton technology for medical and industrial use, today announced that it will release financial and business results for the third quarter 2024 after the close of trading on Monday, October 28, 2024. Management will host a conference call beginning at 1:30 p.m. PT / 4:30 p.m. ET to discuss the financial results and recent business developments. A live webcast of the event will be available in the "Investors" section of the Company's website at www.eksobionics.com, or by clicking here. Investors interested in listening to the conference call may do so
SAN RAFAEL, Calif., July 29, 2024 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (NASDAQ:EKSO) (the "Company" or "Ekso Bionics"), an industry leader in exoskeleton technology for medical and industrial use, today reported financial results for the three and six months ended June 30, 2024. Recent Highlights and Accomplishments Reported revenues of $5.0 million in the second quarter of 2024Initial Medicare claims for Ekso Indego Personal are currently pending reimbursementSold a total of 37 EksoHealth devices in the second quarter of 2024Achieved gross margin of 53% for the quarter ended June 30, 2024 "We are pleased with our significant progress in the second quarter o
SAN RAFAEL, Calif., July 22, 2024 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (NASDAQ:EKSO) (the "Company"), an industry leader in exoskeleton technology for medical and industrial use, today announced that it will release financial and business results for the second quarter 2024 after the close of trading on Monday, July 29, 2024. Management will host a conference call beginning at 1:30 p.m. PT / 4:30 p.m. ET to discuss the financial results and recent business developments. A live webcast of the event will be available in the "Investors" section of the Company's website at www.eksobionics.com, or by clicking here. Investors interested in listening to the conference call may do so b
Aims To Improve Patient Quality Of Life For Those With Spinal Cord And Brain Injuries, Multi-Trauma, Amputations, Stroke, Multiple Sclerosis, And Pain
Lake Street analyst Ben Haynor initiates coverage on Ekso Bionics Holdings (NASDAQ:EKSO) with a Buy rating and announces Price Target of $2.5.
HC Wainwright & Co. analyst Swayampakula Ramakanth maintains Ekso Bionics Holdings (NASDAQ:EKSO) with a Buy and raises the price target from $9.25 to $10.
10-Q - EKSO BIONICS HOLDINGS, INC. (0001549084) (Filer)
8-K - EKSO BIONICS HOLDINGS, INC. (0001549084) (Filer)
8-K - EKSO BIONICS HOLDINGS, INC. (0001549084) (Filer)
SC 13G/A - EKSO BIONICS HOLDINGS, INC. (0001549084) (Subject)
SC 13G - EKSO BIONICS HOLDINGS, INC. (0001549084) (Subject)
4 - EKSO BIONICS HOLDINGS, INC. (0001549084) (Issuer)
4 - EKSO BIONICS HOLDINGS, INC. (0001549084) (Issuer)
4 - EKSO BIONICS HOLDINGS, INC. (0001549084) (Issuer)